Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023
SEATTLE, April 17, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resist ...
VISTA expression in patients with advanced solid tumors: A potential biomarker in VISTA-101 clinical trial
Thierry Guillaudeux, PhD, Chief Scientific Officer American Association for Cancer Research (AACR) Annual Meeting 2023 | April 16, 2023
Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors
VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by end of 2023 SEATTLE, April 12, 2023 -- Ki ...
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
Opened a Phase 1/2 clinical study of VISTA Targeting KVA12123 for Advanced Solid Tumors Initial Data Readout Anticipated by End of 2023 Successfully Completed the Reverse Merger with Nasdaq ...
Kineta to Present VISTA Biomarker Data at AACR Annual Meeting 2023
SEATTLE, March 22, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resist ...
Kineta to Present at the Oppenheimer 33rd Annual Healthcare Conference
SEATTLE, March 08, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resist ...
Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board
SEATTLE, March 01, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announce ...
Kineta Completes Reverse Merger with Yumanity Therapeutics
Shares of Kineta to commence trading on Nasdaq under new ticker symbol “KA” on December 19, 2022 Seattle, WA — (December 19, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotech ...
Next-generation immunotherapies to address cancer immune resistance
Thierry Guillaudeux, PhD, Chief Scientific Officer Antibody Engineering & Therapeutics Conference | December 7, 2022
Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference
Seattle, WA — (December 1, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resista ...